ACR Appropriateness Criteria® Noninvasive Clinical Staging of Bronchogenic Carcinoma

Comparison of Diagnostic Accuracy for TNM Stage Among Whole-Body MRI and Coregistered PET/MRI Using 1.5-T and 3-T MRI Systems and Integrated PET/CT for Non-Small Cell Lung Cancer

OBJECTIVE. The purpose of this study was to compare diagnostic accuracy of TNM stage for whole-body MRI and coregistered PET/MRI using 1.5-T and 3-T MRI systems and PET/CT in patients with non-small cell lung cancer (NSCLC). SUBJECTS AND METHODS. A total of 104 patients with pathologically diagnosed NSCLC underwent whole-body MRI at 1.5 T and 3T and integrated PET/CT, as well as a combination of surgical, pathologic, or follow-up examinations. Whole-body MR images obtained by the five sequences were combined with the PET part of the PET/CT using proprietary software for the PET/MRI studies. The TNM stage obtained with all methods was visually assessed. Kappa statistics were used to determine agreement between TNM stage assessment and final diagnoses, and the McNemar test was used to compare diagnostic accuracy of all methods. RESULTS. Findings of TNM stage on whole-body MRI using 3-T (κ, 0.87; p < 0.0001) and 1.5-T (κ, 0.83; p < 0.0001) systems and for coregistered PET/MRI using a 3-T system (PET/MRI_3T; κ, 0.85; p < 0.0001) were rated as significant and almost perfect, and findings for coregistered PET/MRI using a 1.5-T system (PET/MRI_1.5T; κ, 0.80; p < 0.0001) and PET/CT (κ, 0.73; p < 0.0001) were rated significant and substantial. Diagnostic accuracy of whole-body MRI using the 3-T system was 88.5% (92/104; p = 0.0002, and using the 1.5-T system it was 84.6% (88/104; p = 0.004); results for PET/MRI_3T and PET/MRI_1.5T were 86.5% (90/104; p = 0.001) and 81.7% (85/104; p = 0.03), respectively, which were both significantly better than accuracy of results for PET/CT at 76.0% (79/104). Moreover, diagnostic accuracy of whole-body MRI using a 3-T system was significantly higher than that of PET/MRI using a 1.5-T system (p = 0.02). CONCLUSION. Whole-body MRI and coregistered PET/MRI using 3-T and 1.5-T systems are as accurate or more accurate than PET/CT, whereas differences between 3-T and 1.5-T MRI systems are not considered significant.

Task-Based Model Observer Assessment of A Partial Model-Based Iterative Reconstruction Algorithm in Thoracic Oncologic Multidetector CT

To investigate the impact of a partial model-based iterative reconstruction (ASiR-V) on image quality in thoracic oncologic multidetector computed tomography (MDCT), using human and mathematical model observers. Twenty cancer patients examined with regular-dose thoracic-abdominal-pelvic MDCT were retrospectively included. Thoracic images reconstructed using a sharp kernel and filtered back-projection (reference) or ASiR-V (0-100%, 20% increments; follow-up) were analysed by three thoracic radiologists. Advanced quantitative physical metrics, including detectability indexes of simulated 4-mm-diameter solid non-calcified nodules and ground-glass opacities, were computed at regular and reduced doses using a custom-designed phantom. All three radiologists preferred higher ASiR-V levels (best = 80%). Increasing ASiR-V substantially decreased noise magnitude, with slight changes in noise texture. For high-contrast objects, changing the ASiR-V level had no major effect on spatial resolution; whereas for lower-contrast objects, increasing ASiR-V substantially decreased spatial resolution, more markedly at reduced dose. For both high- and lower-contrast pulmonary lesions, detectability remained excellent, regardless of ASiR-V and dose levels, and increased significantly with increasing ASiR-V levels (all p < 0.001). While high ASiR-V levels (80%) are recommended to detect solid non-calcified nodules and ground-glass opacities in regular-dose thoracic oncologic MDCT, care must be taken because, for lower-contrast pulmonary lesions, high ASiR-V levels slightly change noise texture and substantially decrease spatial resolution, more markedly at reduced dose.

Appropriateness and clinical outcome of chest computed tomography without intravenous contrast: A study conducted in Pakistan

BACKGROUND

Chest computed tomography (CT), including high-resolution CT (HRCT), has become an integral part of modern healthcare. It enables the physician to arrive at a diagnosis using a noninvasive approach. Our practice has shown that various chest CT scans without intravenous (IV) contrast, including HRCT, have no proper clinical indication. For the same reason, we have assessed the appropriateness of chest CT without IV contrast based on the evidence-based American College of Radiology (ACR) appropriateness criteria.

METHODS

Chest CT scans without IV contrast were reviewed to evaluate if the examination was based upon the evidence-based ACR appropriateness criteria. All clinical indications, positive physical examination findings, laboratory test findings, and radiological records submitted at the time of chest CT were reviewed.

RESULTS

Of 1205 CT scans, 538 (44.6%) were considered "inappropriate," 367 (30.4%) were considered "appropriate," and 300 (24.8%) were considered "may be appropriate." CT scans were performed on 241 (20.0%) patients with no clinical history, whereas 148 (12.3%) examinations in patients aged < 40 years were performed with no positive physical finding. Positive results that affected the management were 4.43 times more likely to be considered appropriate than inappropriate (adjusted odds ratio, 4.43; 95% confidence interval, 1.81-10.87).

CONCLUSIONS

This study showed a high percentage of chest CT scans without IV contrast examinations not meeting the ACR appropriateness criteria. Chest CT is a valuable tool for evaluation of chest diseases only in the presence of adequate detailed history and physical examination.

Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients

PURPOSE

To prospectively compare the capabilities for TNM classification and assessment of clinical stage and operability among whole-body magnetic resonance (MR) imaging, coregistered positron emission tomographic (PET)/MR imaging with and without MR signal intensity (SI) assessment, and integrated fluorine 18 fluorodeoxyglucose (FDG) PET/computed tomography (CT) in non-small cell lung cancer (NSCLC) patients.

MATERIALS AND METHODS

The institutional review board approved this study, and written informed consent was obtained from each patient. One hundred forty consecutive NSCLC patients (75 men, 65 women; mean age, 72 years) prospectively underwent whole-body MR imaging, FDG PET/CT, conventional radiologic examinations, and surgical, pathologic, and/or follow-up examinations. All factors and clinical stage and operability were then visually assessed. All PET/MR examinations were assessed with and without SI assessment. One examination used anatomic, metabolic, and relaxation-time information, and the other used only anatomic and metabolic information. κ statistics were used for assessment of all factors and clinical stages with final diagnoses. McNemar test was used to compare the capability of all methods to assess operability.

RESULTS

Agreements of assessment of every factor (κ = 0.63-0.97) and clinical stage (κ = 0.65-0.90) were substantial or almost perfect. Regarding capability to assess operability, accuracy of whole-body MR imaging and PET/MR imaging with SI assessment (97.1% [136 of 140]) was significantly higher than that of MR/PET without SI assessment and integrated FDG PET/CT (85.0% [119 of 140]; P < .001).

CONCLUSION

Accuracies of whole-body MR imaging and PET/MR imaging with SI assessment are superior to PET/MR without SI assessment and PET/CT for identification of TNM factor, clinical stage, and operability evaluation of NSCLC patients.

Role of imaging in diagnosis, staging and follow-up of lung cancer

PURPOSE OF REVIEW

Primary lung cancer is still the number one cause of cancer death worldwide. Screening, detection and staging of lung cancer are important because the only potentially curative therapy today is surgical resection of early-stage lung cancer.

RECENT FINDINGS

Different imaging techniques can be used in these different processes. Recent advances in computed tomography (CT) technology have allowed investigation of novel methods for the evaluation of lung cancer. Recent advances in magnetic resonance technology and administration of contrast media have further improved the image quality and diagnostic capability of magnetic resonance. Positron emission tomography (PET)/CT has been shown to be superior to stand-alone PET or CT in the evaluation of lymph nodes and in the detection of distant metastases.

SUMMARY

The current recommended imaging required for lung cancer staging is CT of the thorax and PET/CT from skull base to mid-thigh. However, with the recent developments in the armamentarium of imaging techniques, the choice of one of these techniques can be directed by the presence of a technique in a local hospital and/or by the presence of an experienced person at that time.

Appropriateness of imaging for lung cancer staging in a national cohort

PURPOSE

Optimizing evidence-based care to improve quality is a critical priority in the United States. We sought to examine adherence to imaging guideline recommendations for staging in patients with locally advanced lung cancer in a national cohort.

METHODS

We identified 3,808 patients with stage IIB, IIIA, or IIIB lung cancer by using the national Department of Veterans Affairs (VA) Central Cancer Registry (2004-2007) and linked these patients to VA and Medicare databases to examine receipt of guideline-recommended imaging based on National Comprehensive Cancer Network and American College of Radiology Appropriateness Criteria. Our primary outcomes were receipt of guideline-recommended brain imaging and positron emission tomography (PET) imaging. We also examined rates of overuse defined as combined use of bone scintigraphy (BS) and PET, which current guidelines recommend against. All imaging was assessed during the period 180 days before and 180 days after diagnosis.

RESULTS

Nearly 75% of patients received recommended brain imaging, and 60% received recommended PET imaging. Overuse of BS and PET occurred in 25% of patients. More advanced clinical stage and later year of diagnosis were the only clinical or demographic factors associated with higher rates of guideline-recommended imaging after adjusting for covariates. We observed considerable regional variation in recommended PET imaging and overuse of combined BS and PET.

CONCLUSION

Receipt of guideline-recommended imaging is not universal. PET appears to be underused overall, whereas BS demonstrates continued overuse. Wide regional variation suggests that these findings could be the result of local practice patterns, which may be amenable to provider education efforts such as Choosing Wisely.

Modern diagnostic and therapeutic interventional radiology in lung cancer

Imaging has an important role in the multidisciplinary management of primary lung cancer. This article reviews the current state-of-the-art imaging modalities used for the evaluation, staging and post-treatment follow-up and surveillance of lung cancers, and image-guided percutaneous techniques for biopsy to confirm the diagnosis and for local therapy in non-surgical candidates.

Cerebral staging of lung cancer: is one single contrast-enhanced T1-weighted three-dimensional gradient-echo sequence sufficient?

INTRODUCTION

Gadolinium-enhanced magnetic resonance imaging (MRI) is the gold standard for cerebral staging in thoracic oncology. We hypothesize that a minimalist examination, consisting of a single contrast-enhanced T1-weighted three-dimensional gradient-echo sequence (CE 3D-GRE), would be sufficient for the cerebral staging of nonsymptomatic lung cancer patients.

METHODS

Seventy nonsymptomatic patients (50 % men; 62 years ± 10.2) referred for cerebral staging of a lung cancer were retrospectively included. All underwent a standard 3 T MRI examination with T1, FLAIR, T2* GRE, diffusion, and CE 3D-GRE sequences, for a total examination time of 20 min. The sole CE 3D-GRE (acquisition time: 6 min) was extracted and blindly interpreted by two radiologists in search of brain metastases. Hemorrhagic features of potential lesions and relevant incidental findings were also noted. Discrepant cases were reviewed by a third reader. The full MRI examination and follow-up studies were used as a reference to calculate sensitivity and specificity of the sole CE 3D-GRE.

RESULTS

Thirty-eight point six percent (27 out of 70) of the patients had brain metastases. Performances and reader's agreement with the sole CE 3D-GRE sequence were excellent for the diagnosis of brain metastases (sensitivity=96.3 %, specificity=100 %, κ=0.91) and incidental findings (sensitivity=85.7 %, specificity=100 %, κ=0.62) but insufficient for the identification of hemorrhages within the metastases (sensitivity=33.3 %, specificity=85.7 %, κ=0.47).

CONCLUSIONS

In the specific case of lung cancer, cerebral staging in nonsymptomatic patients can be efficiently achieved with a minimalistic protocol consisting of a single CE 3D-GRE sequence, completed if positive with a T2* sequence for hemorrhagic assessment, thus halving appointment delays.

Guidelines for multimodality radiological staging of lung cancer

Lung cancer is among the most common type of cancers and is a leading cause of cancer-related deaths with smoking representing the leading risk factor. It is classified into non-small cell lung cancer (NSCLC) representing 70-80% of cases and small cell lung cancer (SCLC) which has neuroendocrine properties with poor outcome. Staging of NSCLC is based on the TNM classification system while SCLC was usually classified into limited and extensive disease, though the use of TNM staging system for SCLC is recommended. Imaging studies are used to determine the pre-operative staging of lung cancer. Accurate radiological staging is essential to determine tumor resectability as well as to avoid futile surgeries and to assess patient's outcome. Moreover, radiological examinations are used for the evaluation of tumor response to treatment. This manuscript will review the utilization of imaging studies in the management of lung cancer based on the most recent guidelines by the National Comprehensive Cancer Network (NCCN).

Advances in oncologic imaging: update on 5 common cancers

Imaging has become a pivotal component throughout a patient's encounter with cancer, from initial disease detection and characterization through treatment response assessment and posttreatment follow-up. Recent progress in imaging technology has presented new opportunities for improving clinical care. This article provides updates on the latest approaches to imaging of 5 common cancers: breast, lung, prostate, and colorectal cancers, and lymphoma.